title: Bioartificial organ support for hepatic, renal, and hematologic failure.
abstract: The current strategy to the treatment of SIRS and MODS uses a multidisciplinary approach that emphasizes supportive therapy. Herein, we have presented a futuristic approach that focuses on replacing the function of failed organs using bioartificial technology (Table 1). Bioartificial organ technology may allow the intensivist to provide physiologic organ replacement either as a bridge to transplantation or as a "time-buying" element until native organs that have become acutely dysfunctional or nonfunctional in a variety of clinical settings, can recover their function or regenerate their mass. As bioartificial organ technology matures, it is conceivable as an ultimate goal that non-immunogenic bioartificial organs would be miniaturized or redesigned and acutely placed within the intracorporeal space as replacement organs.
authors.affiliation: Department of Medical Affairs and New Technology Development, Vitagen Inc., La Jolla, California, USA.
authors.forename: P J
authors.initials: PJ
authors.lastname: Maguire
authors.forename: C
authors.initials: C
authors.lastname: Stevens
authors.forename: H D
authors.initials: HD
authors.lastname: Humes
authors.forename: A
authors.initials: A
authors.lastname: Shander
authors.forename: N A
authors.initials: NA
authors.lastname: Halpern
authors.forename: S M
authors.initials: SM
authors.lastname: Pastores
mesh_terms: D021522:Bioartificial Organs / Q000639:trends*; D019149:Bioreactors; D001802:Blood Substitutes; D006801:Humans; D007688:Kidneys, Artificial / Q000639:trends*; D017093:Liver Failure / Q000628:therapy*; D019164:Liver, Artificial / Q000639:trends*; D051437:Renal Insufficiency / Q000628:therapy*
chemical_list: D001802:Blood Substitutes